Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3172320 | 0.79 | CHRNB2 (0.58) | HRH3SMN1; SMN2ALDH1A1HTTCHRNB2 | |
| SCHEMBL20836288 | 0.78 | HRH3 (0.53) | HRH3SMN1; SMN2CXCR4NCF1ALDH1A1 | |
| SCHEMBL4970159 | 0.78 | CHRNB2 (0.72) | HRH3CXCR4NCF1ALDH1A1MAPT | |
| SCHEMBL15260468 | 0.77 | HRH3 (0.56) | HRH3SMN1; SMN2CXCR4NCF1ALDH1A1 | |
| SCHEMBL14606256 | 0.77 | HRH3 (0.52) | HRH3SMN1; SMN2CXCR4NCF1ALDH1A1 | |
| SCHEMBL14514820 | 0.77 | MAPT (0.49) | HRH3SMN1; SMN2CXCR4NCF1ALDH1A1 | |
| SCHEMBL18427235 | 0.77 | HRH3 (0.47) | HRH3SMN1; SMN2CXCR4NCF1ALDH1A1 | |
| SCHEMBL15366942 | 0.77 | HRH3 (0.47) | HRH3SMN1; SMN2CXCR4NCF1ALDH1A1 | |
| SCHEMBL465728 | 0.77 | NCF1 (0.47) | HRH3SMN1; SMN2CXCR4NCF1ALDH1A1 | |
| SCHEMBL12241726 | 0.77 | CYP11B2 (0.53) | HRH3SMN1; SMN2CXCR4NCF1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112888684-B | 4-pyrimidin-5-ylmethyl-morpholine derivatives and their use as medicaments | 勃林格殷格翰国际有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-112888684-B | 4-pyrimidin-5-ylmethyl-morpholine derivatives and their use as medicaments | 勃林格殷格翰国际有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-112888684-B | 4-pyrimidin-5-ylmethyl-morpholine derivatives and their use as medicaments | 勃林格殷格翰国际有限公司 | 2023-10-10 | — | — | CN | disclosed |
| EP-3867245-B1 | 4-PYRIMIDIN-5-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2022-12-07 | — | — | EP | disclosed |
| EP-3867245-B1 | 4-PYRIMIDIN-5-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2022-12-07 | — | — | EP | disclosed |
| CN-112888684-A | 4-pyrimidin-5-ylmethyl-morpholine derivatives and their use as medicaments | 勃林格殷格翰国际有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-112888684-A | 4-pyrimidin-5-ylmethyl-morpholine derivatives and their use as medicaments | 勃林格殷格翰国际有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-112888684-A | 4-pyrimidin-5-ylmethyl-morpholine derivatives and their use as medicaments | 勃林格殷格翰国际有限公司 | 2021-06-01 | — | — | CN | disclosed |
| US-20200123140-A1 | 4-Pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-04-23 | — | — | US | disclosed |
| US-20200123140-A1 | 4-Pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-04-23 | — | — | US | disclosed |
| US-20200123140-A1 | 4-Pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-04-23 | — | — | US | disclosed |
| WO-2020079040-A1 | 4-PYRIMIDIN-5-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020079040-A1 | 4-PYRIMIDIN-5-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123140-A1 | 4-Pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament | GRIN2C, GRIN2A, GRIN3A | HRH3 578/4885SMN1; SMN2 1214/4885CXCR4 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.